beyond pink team
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us
 If you are Breast Cancer Survivor and  you would like to contribute your story to our Newsletter, 
​please send us a message here.
DOWNLOAD Current NewsletteR

Categories

All
Advocacy
Bone Health
Breast Density
Breast Disease
Caregivers
COVID 19
COVID-19
Emotional Support
Environment
Exercise
Fatigue
Financial
Gender
Genetic Testing
Grief
High Risk
Hormone Replacement Therapy
Ignite
Implants
Intimacy After Cancer
LGBTQ
Lymphedema
Mammography
Meditation
Men
Mental Health
Metastasis
MRI
NBCC
Nutrition
Obesity
Pain
Pregnancy
Prevention
Radiation
Reconstruction
Reduce Risk
Rehabilitation
Screening
Sex
Side Effects
Support Groups
Surgery
Survivor
Survivorship
Treatment
Vaccine
Yoga
Young Women

Archives

January 2023
October 2022
July 2022
April 2022
January 2022
October 2021
July 2021
April 2021
January 2021
October 2020
July 2020
April 2020
January 2020
October 2019
July 2019
April 2019
January 2019
October 2018
July 2018
April 2018
January 2018
October 2017
July 2017
April 2017
January 2017
October 2016
July 2016
April 2016
January 2016
October 2015
July 2015
April 2015
January 2015
October 2014
July 2014
April 2014
January 2014
October 2013
July 2013
April 2013
January 2013
October 2012
July 2012
April 2012
January 2012
October 2011
July 2011
April 2011
January 2011
October 2010
July 2010
April 2010
January 2010
October 2009
July 2009
April 2009
January 2009
October 2008
July 2008
April 2008
January 2008
October 2007
July 2007
April 2007
January 2007
October 2006
July 2006
April 2006
January 2006
October 2005
July 2005
April 2005
January 2005
October 2004
July 2004
April 2004
January 2004

BREAST CANCER INDEX: New Tool to Help Guide Cancer Therapy

1/1/2017

0 Comments

 
By Kim Maxfield RN, CCRC - Clinical Research Nurse

Having the diagnosis of breast cancer is scary and the treatment benefit for long term endocrine therapy after 5 years is still uncertain. Patients with ER+ breast cancer usually have a good prognosis; however, the risk of the cancer recurring before and after 5 years is similar.

How long does a patient need to be on anti-estrogen therapy?
Initially, it was thought that 5 years was adequate. Recent studies have shown that for some women, an additional 5 years of anti-estrogen therapy is beneficial. For women who were recurrence free at 5 years, only about 3- 5% benefited from an additional 5 years of treatment.

It is also important to weigh the benefits of continuing treatment to the potential risks and side effects.
Some reported side effects of anti-estrogen therapy are:
Long term safety concerns: Endometrial cancer, osteoporosis, cataracts, bone fractures, blood clots and heart disease.
Day to day tolerability issues: Vaginal dryness, itchiness and discharge, hot flashes or night sweats, joint stiffness or pain, muscle pain and sexual dysfunction.

The Breast Cancer Index test, made by BioTheranostics can help to answer some of these questions. The Breast Cancer Index uses tissue from the original Breast Cancer surgery and analyzes seven genes that can influence how likely the cancer is to come back 5 to 10 years after diagnosis, as well as how likely a woman is to benefit from an additional 5 years of treatment.

The Breast Cancer Index result has two scores. The first score predicts the risk of the cancer coming back beyond 5 years (years 5-10). Scores range from 0-10. Cancers with scores of 0-5 are classified as having low risk of late recurrence. Cancers with scores of 5.1-10 are classified as having a high risk of late recurrence.

The second score predicts the likelihood of benefit from an additional 5 years of anti-estrogen therapy.
The results are reported as low likelihood of benefit or high likelihood of benefit.

Who is eligible for the breast cancer index?
• Patients that were diagnosed with early stage (stage I-III) breast cancer
• The cancer was hormone-receptor positive and HER2-negative 
• There was no cancer in the lymph nodes (lymph node-negative disease)
• Patients that have been taking hormonal therapy for 4-5 years and want to know if taking hormonal therapy for more time will be beneficial

The BCI offers a validated predictive tool that women along with their physician can use to decide treatment strategies that is right for them. The test is currently not approved by the US Food and Drug Administration. Medicare covers the BCI at a predetermined rate with no fees charged to the patient as long as the eligibility criteria are met. Many commercial insurance companies also reimburse for the BCI but be sure that you or your physician’s office checks for coverage before ordering the test.

BioTheranostics (the company that makes the test) does have a patient advocate team to help with verifying insurance coverage and obtaining reimbursement. They also have a patient assistance program that helps to pay for testing.

​To contact the patient advocate team you can call 877-886-6739 or patientadvocates@biotheranostics.com. There are new treatments and tools being studied all the time for breast cancer patients. The Breast Cancer Index is one of the new tools being used to help with long term treatment decisions and is being reimbursed by more insurance companies daily. For patients that are interested in more information or would like to have the test done, please talk to you oncologist to see if you qualify and if your insurance will cover the test. 

Read Full Newsletter
0 Comments



Leave a Reply.

CONTACT US

Beyond Pink TEAM
c/o Jeanne Olson, Treasurer
1407 Asbury Lane
Waterloo, IA 50701
​beyondpinkteam@gmail.com
(319) 239-3706
©2020 Beyond Pink TEAM
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us